Metro (MRU) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
4 Mar, 2026Executive summary
Q3 sales reached $6.871 billion, up 3.3% year-over-year, with food same-store sales up 1.9% and pharmacy same-store sales up 5.5%.
EBITDA grew 5.7% to $656 million, and adjusted EPS increased 12.6% to $1.52; fully diluted EPS rose 13.0% to $1.48.
Gross margin improved to 19.8% from 19.6% last year, driven by productivity gains and shrink improvement.
Online sales rose 14.4%, supported by expanded delivery partnerships and Click and Collect services.
Five new food stores were opened, supporting discount banner expansion.
Financial highlights
Adjusted net earnings were $332 million, up 8.8% year-over-year; net earnings reached $323 million, up 9.0%.
Operating expenses were $702 million, or 10.2% of sales, consistent with last year.
Net financial costs decreased to $45.3 million from $46.6 million, mainly due to lower interest expense.
Capital expenditures totaled $146 million, down $41 million, reflecting completion of automated distribution centers.
Effective tax rate dropped to 24.1% from 25.9%, aided by a provincial tax holiday.
Outlook and guidance
Continued focus on discount banner expansion, with 14 new stores planned for fiscal 2025.
Management expects modest SG&A leverage in coming quarters as duplicate costs have been lapped.
Sustained investments in retail networks and supply chain are expected to drive long-term growth.
Focus shifts to realizing efficiency gains after major supply chain investments.
Efforts to deliver value through merchandising, private label, and loyalty programs continue amid economic uncertainty.
Latest events from Metro
- Q2 sales up 5.5%, adjusted EPS up 12.1%, and online sales grew 26.2% year-over-year.MRU
Q2 20259 Jul 2026 - Sales up 3.5% to CAD 6.65B, but net earnings fell 14.6% amid automation and cost pressures.MRU
Q3 20249 Jul 2026 - Q4 saw strong sales and margin gains, supply chain completion, and profit growth expected in 2025.MRU
Q4 20248 Jul 2026 - Strong results, board re-elections, and strategic growth plans highlighted; auditor term limit proposal rejected.MRU
AGM 20258 Jul 2026 - Q2 sales rose 4.1% to CAD 5.1B, with strong pharmacy, discount, and online growth.MRU
Q2 202622 Apr 2026 - Sales up 2.9%, adjusted EPS up 7.8%, online sales up 18.6%, and dividend raised 10.4%.MRU
Q1 20254 Mar 2026 - Q4 sales and earnings rose despite supply chain disruptions, with a strong FY 2026 outlook.MRU
Q4 20254 Mar 2026 - Sales up 3.3%, adjusted EPS up 5.5%, net earnings down 12.8% on one-time costs; dividend up 10.1%.MRU
Q1 20264 Mar 2026